

Resource Summary Report

Generated by ASWG on Aug 9, 2026

Syrian Hamster Anti-CD28 Monoclonal Antibody, Unconjugated, Clone 37.51

RRID:AB_394763

Type: Antibody

Proper Citation

BD Biosciences Cat# 553294, RRID:AB_394763

Antibody Information

URL: http://antibodyregistry.org/AB_394763

Proper Citation: BD Biosciences Cat# 553294, RRID:AB_394763

Target Antigen: CD28

Clonality: monoclonal

Comments: Flow cytometry, Immunohistochemistry-frozen

Antibody Name: Syrian Hamster Anti-CD28 Monoclonal Antibody, Unconjugated, Clone 37.51

Description: This monoclonal targets CD28

Target Organism: mouse

Clone ID: 37.51

Antibody ID: AB_394763

Vendor: BD Biosciences

Catalog Number: 553294

Record Creation Time: 20250820T042753+0000

Record Last Update: 20250820T190227+0000

Ratings and Alerts

No rating or validation information has been found for Syrian Hamster Anti-CD28 Monoclonal Antibody, Unconjugated, Clone 37.51.

No alerts have been found for Syrian Hamster Anti-CD28 Monoclonal Antibody, Unconjugated, Clone 37.51.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 67 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Pfab C, et al. (2026) Protocol for potent activation of T cells using BPI-stimulated murine bone marrow-derived cells. STAR protocols, 7(2), 104519.

Jiang C, et al. (2026) TCR-NF- κ B signaling activates the SENP1-NR4A1 axis to fine-tune effector activation of CD8⁺ T cells. Cell reports, 45(3), 117102.

Guleed S, et al. (2026) CD8⁺ T cell responses recognizing immunodominant Chlamydia antigens fail to protect against infection. iScience, 29(4), 115242.

Ponessa JJ, et al. (2026) Alveolar macrophages inhibit emphysematous pathology via expression of carbonic anhydrase 4. Cell reports, 45(5), 117315.

Agesta A, et al. (2026) The transcription factor Eomes drives a stemness program in CD4⁺ T cells that promotes anti-tumor immunity in response to immunotherapy. Immunity, 59(7), 1876.

Philbrook P, et al. (2026) Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming. Cancer immunology research, 14(4), 640.

Xie X, et al. (2026) Eos plays a critical role in Treg homeostasis and modulates the function of recirculating thymic Tregs in the control of Treg development. Cell reports, 45(1), 116838.

Singh D, et al. (2026) Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity. Cancer research, 86(5), 1252.

Cui J, et al. (2026) Translation factor eIF4G2 directs CD8⁺ T cell lineage commitment by selectively enabling the IL-7 receptor response. iScience, 29(4), 115313.

Clark ML, et al. (2025) Mitochondrial complex IV remodeling in tumor-associated macrophages amplifies interferon signaling and promotes anti-tumor immunity. Immunity, 58(7), 1670.

Wu Y, et al. (2025) DA-DRD5 signaling reprograms B cells to promote CD8+ T cell-mediated antitumor immunity. *Cell reports*, 44(3), 115364.

Zhao CN, et al. (2025) *Phocaeicola vulgatus* induces immunotherapy resistance in hepatocellular carcinoma via reducing indoleacetic acid production. *Cell reports. Medicine*, 102370.

Li B, et al. (2025) Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis. *Cell*, 188(14), 3823.

Phelps CM, et al. (2025) Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy. *Cell*.

Li J, et al. (2025) Monocyte/macrophage-derived interleukin-15 mediates the pro-inflammatory phenotype of CD226+ B cells in type 1 diabetes. *EBioMedicine*, 120, 105946.

Kondo T, et al. (2025) Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity. *Cell*, 188(9), 2372.

Osaki M, et al. (2025) Soluble CTLA-4 regulates immune homeostasis and promotes resolution of inflammation by suppressing type 1 but allowing type 2 immunity. *Immunity*, 58(4), 889.

Rao C, et al. (2025) Beta cell extracellular vesicle PD-L1 as a novel regulator of CD8+ T cell activity and biomarker during the evolution of type 1 diabetes. *Diabetologia*, 68(2), 382.

Rao C, et al. (2024) Beta cell extracellular vesicle PD-L1 as a novel regulator of CD8+ T cell activity and biomarker during the evolution of Type 1 Diabetes. *bioRxiv : the preprint server for biology*.

Ichiyama K, et al. (2024) Transcription factor *Ikzf1* associates with *Foxp3* to repress gene expression in Treg cells and limit autoimmunity and anti-tumor immunity. *Immunity*, 57(9), 2043.